Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)”

183 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 183 results

Testing effectiveness (Phase 2)UnknownNCT04502394
What this trial is testing

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Who this might be right for
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Kartos Therapeutics, Inc. 84
Testing effectiveness (Phase 2)WithdrawnNCT05966233
What this trial is testing

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent
Fondazione Italiana Linfomi - ETS
Early research (Phase 1)Ended earlyNCT03558750
What this trial is testing

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Who this might be right for
Recurrent Central Nervous System LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Central Nervous System Lymphoma+1 more
Vanderbilt-Ingram Cancer Center 6
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics 86
Testing effectiveness (Phase 2)Ended earlyNCT03123393
What this trial is testing

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Calithera Biosciences, Inc 49
Testing effectiveness (Phase 2)Ended earlyNCT05626322
What this trial is testing

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 6
Early research (Phase 1)Study completedNCT02549651
What this trial is testing

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Who this might be right for
Diffuse Large B-Cell Lymphoma
MedImmune LLC 32
Early research (Phase 1)Study completedNCT03340766
What this trial is testing

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen 31
Testing effectiveness (Phase 2)Study completedNCT03259529
What this trial is testing

Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
St. Petersburg State Pavlov Medical University 30
Testing effectiveness (Phase 2)WithdrawnNCT04607772
What this trial is testing

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc
Large-scale testing (Phase 3)Study completedNCT02763319
What this trial is testing

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Incyte Corporation 453
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07249905
What this trial is testing

This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma

Who this might be right for
LymphomaWaldenström Macroglobulinemia (WM)DLBCL - Diffuse Large B Cell Lymphoma+5 more
ModeX Therapeutics, An OPKO Health Company 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06886139
What this trial is testing

TRS005 in Patients With CD20-positive R/R DLBCL.

Who this might be right for
CD20-positive Diffuse Large B-Cell Lymphoma
Zhejiang Teruisi Pharmaceutical Inc. 139
Very early researchLooking for participantsNCT04512716
What this trial is testing

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Who this might be right for
B-ALLDLBCLB ALL+8 more
Memorial Sloan Kettering Cancer Center 12
Testing effectiveness (Phase 2)UnknownNCT05498636
What this trial is testing

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

Who this might be right for
DLBCL
The Affiliated Hospital of Qingdao University 67
Early research (Phase 1)Study completedNCT03467373
What this trial is testing

Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Who this might be right for
B-Cell LymphomaNon-Hodgkin Lymphoma
Hoffmann-La Roche 111
Testing effectiveness (Phase 2)Ended earlyNCT03954106
What this trial is testing

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

Who this might be right for
DLBCLNeurotoxicity Syndromes
Jazz Pharmaceuticals 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541
What this trial is testing

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more
Mayo Clinic 10
Testing effectiveness (Phase 2)Ended earlyNCT05328102
What this trial is testing

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large-cell B-cell Lymphoma
Xencor, Inc. 3
Testing effectiveness (Phase 2)Study completedNCT01472887
What this trial is testing

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Who this might be right for
Diffuse Large B-cell Lymphoma
Sanofi 61
Load More Results